Johnson & Johnson (NYSE:JNJ)

Net cash flows from operating activities exhibited some fluctuation over the five-year period. Beginning at US$23,410 million in 2021, these flows decreased to US$21,194 million in 2022 before recovering to US$22,791 million in 2023. Further increases were observed in 2024 and 2025, reaching US$24,266 million and US$24,530 million respectively. This indicates a generally positive trend in operating cash generation, despite the initial dip.

Free Cash Flow to Equity (FCFE)

FCFE demonstrated significant variability throughout the period. It increased substantially from US$18,768 million in 2021 to US$24,637 million in 2022. A subsequent decline was noted in 2023, with FCFE falling to US$15,514 million. However, a strong recovery occurred in 2024, reaching US$29,893 million, and remained high in 2025 at US$29,335 million. This pattern suggests that FCFE is sensitive to underlying operational and financial decisions, with notable swings in value.

The relationship between net cash flows from operating activities and FCFE is not directly proportional. While operating cash flows generally trended upward, FCFE experienced more pronounced fluctuations. This suggests that factors beyond core operating performance, such as capital allocation decisions, debt financing, and equity issuances or repurchases, significantly influence the amount of cash flow available to equity holders. The substantial increase in FCFE in 2024 and 2025, despite a more moderate increase in operating cash flows, warrants further investigation into the specific drivers of this difference.

Overall, the period shows a company capable of generating substantial cash flow, but with FCFE exhibiting considerable year-to-year changes. The consistency of operating cash flow provides a base, but the variations in FCFE highlight the importance of understanding the company’s capital structure and investment strategies.

The Price to Free Cash Flow to Equity (P/FCFE) ratio exhibited fluctuations over the observed period. Initial values decreased, followed by an increase and subsequent decline, culminating in a substantial rise in the most recent year. This analysis details the observed trends in share price, FCFE per share, and the resulting P/FCFE ratio.

Share Price

The share price experienced a decline from US$166.19 in 2021 to US$156.55 in 2023. A modest increase to US$157.25 was noted in 2024, before a significant jump to US$240.86 in 2025.

FCFE per Share

FCFE per share increased from US$7.14 in 2021 to US$9.46 in 2022. A decrease to US$6.44 was observed in 2023, followed by a substantial increase to US$12.42 in 2024, and a slight decrease to US$12.17 in 2025.

P/FCFE Ratio

The P/FCFE ratio began at 23.28 in 2021, decreasing to 16.73 in 2022. It then rose to 24.31 in 2023, before falling to 12.67 in 2024. The ratio experienced a notable increase to 19.79 in 2025. The fluctuations in the P/FCFE ratio largely reflect the combined effect of changes in share price and FCFE per share.

The decrease in the ratio from 2021 to 2022 was primarily driven by the increase in FCFE per share, which outpaced the decline in share price. The subsequent increase in 2023 was due to the share price decline exceeding the decrease in FCFE per share. The significant drop in 2024 was a result of a substantial increase in FCFE per share. Finally, the increase in 2025 was driven by the large increase in share price.

The most significant change occurred in 2025, with both the share price and the P/FCFE ratio increasing substantially. While FCFE per share remained relatively stable between 2024 and 2025, the increase in share price had a pronounced effect on the P/FCFE ratio.